Welcome to Richmond Pharmacology

Market-leading contract research organisation, specialising in Early Phase Trial Management

Watch our
video

Adaptive
Phase I, II & III

Taking your drug from
First-In-Human to Proof of Concept in less than nine months.

Learn
more

Bridging
Studies

Cost effective, time efficient and safe protocol design.

Bridging Studies

Thorough & Intensive QTc Studies

From advice by renowned experts to competent study conduct and ECG Analysis. All under one roof

TQT 
Studies

Patient Recruitment

Fast, efficient recruitment using our database of 250,000 active potential participants

Find out
more

UK's leading clinical research organisation

Since 2001, Richmond Pharmacology has conducted over 500 Early Phase Studies, delivering exceptional customer service, and exceeding the expectations of our sponsors. We have significant experience in running a range of patient trials, adding value to the studies by incorporating detailed analysis of the cardiovascular effects of drugs.

We are industry leaders in Adaptive Phase I and II studies, Thorough-QT, Japanese Bridging Studies and Patient Recruitment. Our services span consultancy and concept development through to final reporting.

As a sponsor, you will receive a personal and truly strategic experience and our knowledgeable staff will ensure your trial delivers meaningful results.

Our business ethos is unique:
Our business is sustainable, adaptive to change and is led by the same specialists who founded Richmond Pharmacology nineteen years ago. Our founders are involved in each clinical research trial, so you are assured of a personal service throughout.

We are committed to advancing science and improving patient safety. Our revenues are reinvested in the business and the newly developed, not-for-profit research organisation – Richmond Research Institute. The Institute was born from our partnership with St George’s University London and a mutual desire to expand academic research in key fields of cardiology, hepatology, clinical trial methodology and racial and sex differences in human physiology.

From initial contact to the completion of the study, our drug developers and investors find working with us enjoyable and rewarding.

What makes us special

Work with our experts

Conduct your trial in a cost effective and timely manner

Get in touch today

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

What 20 years of clinical research has taught us about our industry and the future of drug development

June 9, 2021
As Richmond Pharmacology approaches its 20th anniversary our co-founder and CEO reflects on the developments, regulatory changes, and innovations within the life science industry in an article in the PharmaTimes.
Read more

Do we still need challenge trials with COVID-19?

April 21, 2021
Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.
Read more

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more